When DOJ Declines a Pharmaceutical Whistleblower Case: The Case Can Still Pay

When the Justice Department declines a pharmaceutical whistleblower case, the whistleblower may still pursue the case and share in a recovery. The decision tells you whether the government is taking the lead. It does not settle whether a drug company paid doctors to prescribe or understated the rebates it owed Medicaid. If you know how those payments or calculations worked inside the business, that knowledge can still matter.

What Does a DOJ Declination Mean?

A declination means the Department of Justice has chosen not to take over a whistleblower’s False Claims Act case. The whistleblower may continue pursuing it on the government’s behalf with pharmaceutical whistleblower lawyers. The pharmaceutical examples below show that this can produce a settlement benefiting the government and a reward for the person who brought the case.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. The ordinary share is 15% to 25% when the government joins and 25% to 30% when it does not. We assess the evidence and the path forward with you and pharmaceutical whistleblower lawyers who understand the conduct at issue.

The government’s role can also extend beyond its choice about taking the lead. In Celgene’s settlement announcement, the Justice Department described a case pursued by a former sales manager and monitored by government offices. The company agreed to pay $280 million over allegations involving promotion of Thalomid and Revlimid for unapproved, uncovered uses and kickbacks to physicians.

Biogen’s Alleged Consulting Needs Followed the Budget

Biogen agreed to a $900 million civil settlement after a former employee pursued a case the government declined. The Justice Department’s September 2022 announcement described alleged speaker honoraria, training fees, consulting fees and meals intended to induce prescriptions for Avonex, Tysabri and Tecfidera.

The whistleblower’s third amended complaint alleged that senior marketing officials decided how many consulting meetings to hold and how much money to pay doctors. Regional marketing staff then had to supply the topics. The complaint put the alleged sequence plainly:

The alleged consulting need followed the budget. That reverses the commercial explanation for hiring a consultant: there is a question to answer, so the business pays someone qualified to answer it.

The complaint also alleged that nobody used the feedback from the meetings. Executive summaries were prepared, but the consultants’ opinions drew no interest. Elsewhere, it described spreadsheets tracking payment opportunities for physicians whose prescribing business management wanted to retain.

The complaint placed compliance paperwork inside the alleged process, too. It alleged that a compliance manager told marketing staff which terminology to use in needs-assessment forms to withstand government inspection. That makes the written business justification part of the allegation. Someone who prepared or reviewed those forms may understand how the stated need differed from the program management had already chosen to fund. We examine the approval trail alongside the payments and meeting records.

The complaint further alleged that Biogen expanded speaker training for Avonex and Tysabri despite already having more trained speakers than it could use. It connected that expansion to an effort to blunt the arrival of Gilenya.

For someone in pharmaceutical sales, marketing or compliance, those are recognizable business decisions. The payment approval and the meeting’s stated purpose can tell different stories. We examine that difference with the people who understand why the program existed and how its participants were chosen.

The Justice Department put the whistleblower’s share at about 30% of the federal proceeds.

A Declined Drug Pricing Qui Tam Settlement at Bristol-Myers Squibb

Bristol-Myers Squibb agreed to pay $75 million to resolve allegations that it underpaid Medicaid drug rebates after the government declined to join the case. In its April 2021 announcement, the Justice Department expressly credited the whistleblower and the pharmaceutical whistleblower lawyers who continued pursuing it.

This declined drug pricing qui tam settlement concerned the numbers used to calculate the government’s rebate. A whistleblower with knowledge of wholesaler contracts and price reporting could recognize the transaction behind that description.

Manufacturers pay quarterly rebates to state Medicaid programs in exchange for coverage of their drugs. Those rebates depend in part on the average manufacturer prices reported to the government. A higher reported average manufacturer price means a larger rebate. A manufacturer that improperly lowers the reported number can shrink the amount it pays back to Medicaid.

The Justice Department described alleged underreporting through two different parts of the wholesaler relationship. Bristol-Myers Squibb allegedly lowered reported average manufacturer price by improperly deducting service fees paid to wholesalers. It also allegedly left out additional value received under price-appreciation provisions in its wholesaler contracts. Both treatments allegedly reduced the rebates owed.

Service Fees in the Medicaid Rebate Calculation

The service-fee allegation concerned a deduction in the manufacturer’s price calculation. Treating a payment to a wholesaler as a price concession reduces the manufacturer’s reported net price. A qualifying service fee receives different treatment. In the alleged Medicaid scheme, taking the deduction made the reported price too low and left the states with smaller rebates.

That puts the contract, the service performed and the calculation beside one another. A person who understands the wholesaler’s work can help explain what the manufacturer actually bought. A person who understands government pricing can explain how that payment entered the report. We connect those accounts to the amount the manufacturer paid back to Medicaid.

Price Appreciation in the Wholesaler Contract

Price appreciation concerns value created when a manufacturer raises its price while a wholesaler holds inventory bought at the earlier price. Contracts can return part of that inventory gain to the manufacturer. The Justice Department alleged that Bristol-Myers Squibb excluded additional value it received through those provisions from reported average manufacturer price.

The alleged omission therefore concerned money coming back through the commercial relationship. The wholesaler agreement explained why the manufacturer received it. The government-price calculation showed how the company treated it. Comparing those records gets to the substance of the allegation much faster than looking at the drug’s advertised price.

Approximately $41 million of the settlement was allocated to the United States, with the remainder going to participating states. The alleged underpayment left state Medicaid programs short and caused the federal government to overpay its share of Medicaid costs. The alleged scheme shifted the cost to taxpayers.

Why the Manufacturer’s Calculations Matter

Medicaid’s rebates depend on prices the manufacturer calculates and reports. That makes the company’s treatment of wholesaler payments central to understanding the alleged underpayment.

Public drug-price figures give an outsider only part of that picture. The Association Between Drug Rebates and List Prices, a 2020 USC Schaeffer Center white paper, found that increases in rebates were associated with increases in list prices. Its analysis used estimated net prices because manufacturers and distribution businesses keep much of their pricing and rebate information confidential.

The paper also explained why the difference between list and net price reaches beyond payments to pharmacy benefit managers:

For an insider, that is where the contracts and calculations become valuable. The aggregate price difference groups together payments that the business records separately. A wholesaler’s fee, a discount and an inventory payment each have a commercial purpose and a treatment in the pricing calculation. We work through those transactions with you to explain what the reported price includes and what it leaves out.

Biogen’s alleged consulting payments and Bristol-Myers Squibb’s alleged rebate underpayments required different kinds of knowledge. One account concerned why physicians received money. The other concerned how the manufacturer reported money moving through its wholesaler relationships. In each, an insider’s understanding gives the payment records their meaning.

What Types of Cases Will the DOJ Pursue?

The Department of Justice has pursued pharmaceutical cases involving physician payments, promotion and drug rebates. It joined Gilead’s speaker-program case while Biogen’s whistleblower pursued similar allegations without government intervention.

In its April 2025 Gilead settlement announcement, the government said it joined a private whistleblower case concerning speaker programs for HIV drugs. Gilead admitted conduct involving payments to high-volume prescribers, desirable travel destinations and repeated program attendance.

Those outcomes show that a declined case can produce a recovery. We assess the particular payments, the people who understood them and the connection to government spending with you. The useful starting point is what your knowledge explains about the company’s conduct.

Your Knowledge Still Deserves a Hearing

If the Justice Department has declined a case involving drug-company payments or pricing, talk with our whistleblower experts about the transactions you know. We connect you with pharmaceutical whistleblower lawyers who understand the physician payments or drug-pricing calculations behind your case. We stay beside you as partners, building the strongest account of the payments, decisions and government money at issue.